Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Senseonics Price Performance

Shares of SENS stock opened at $0.44 on Friday. The stock has a 50 day moving average of $0.49 and a two-hundred day moving average of $0.56. The company has a current ratio of 3.96, a quick ratio of 3.70 and a debt-to-equity ratio of 1.79. Senseonics has a 12 month low of $0.38 and a 12 month high of $1.05. The company has a market capitalization of $235.71 million, a P/E ratio of -3.17 and a beta of 0.91.

Senseonics (NYSE:SENS) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Senseonics had a negative return on equity of 202.32% and a negative net margin of 346.38%. The company had revenue of $8.00 million during the quarter, compared to the consensus estimate of $7.62 million. As a group, equities analysts expect that Senseonics will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Senseonics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Senseonics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after buying an additional 211,128 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after buying an additional 51,000 shares during the period. Virtu Financial LLC bought a new position in shares of Senseonics during the 1st quarter worth approximately $162,000. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Senseonics during the 1st quarter worth approximately $91,000. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.